Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Percheron Therapeutics Limited
PERCurrent price
0.082 AUD
-0.003 AUD (-3.53%)
Last closed
0.085 AUD
Company
www.antisense.com.au
ISIN
AU000000ANP4
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
Australian Securities Exchange
Capitalization
90 642 637 AUD
Yield for 12 month
+32.26 %
1Y
3Y
5Y
10Y
15Y
PER
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Address: L30, Collins Place, Melbourne, VIC, Australia, 3000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
0.32 AUDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+391 307 AUD
Current Quarter
+552 248 AUD
Last Quarter
+552 248 AUD
Current Year
–
Last Year
–
Current Quarter
+545 225 AUD
Last Quarter
+545 225 AUD
Key Figures PER
1 year
3 years
5 years
10 years
EBITDA
-12 097 833 AUD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-54.4 %
PEG Ratio
–
Return On Equity TTM
-123.27 %
Wall Street Target Price
0.32 AUD
Revenue TTM
3 017 430 AUD
Book Value
0.01 AUD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
20.2 %
Dividend Yield
–
Gross Profit TTM
1 572 481 AUD
Earnings per share
-0.01 AUD
Diluted Eps TTM
-0.01 AUD
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PER
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PER
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
50:49
Payout Ratio
–
Last Split Date
10.04.2018
Dividend Date
–
Stock Valuation PER
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
347.0025
Price Sales TTM
30.0397
Enterprise Value EBITDA
-4.4641
Price Book MRQ
8.8584
Financials PER
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PER
For 52 weeks
0.053 AUD
0.14 AUD
50 Day MA
0.094 AUD
Shares Short Prior Month
–
200 Day MA
0.083 AUD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart